OncoMatch/Clinical Trials/NCT07154082
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Is NCT07154082 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TACE (transarterial chemoembolization) combined with targeted/immunotherapy for hepatocellular carcinoma (hcc).
Treatment: TACE (transarterial chemoembolization) combined with targeted/immunotherapy — This study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital , Tongji Medical College, Huazhong University of Science and Technology, are over 18 years old, and have signed the informed consent form to voluntarily participate in this study. Through the neoadjuvant treatment of Apatinib mesylate and Camrelizumab combined with TACE before liver resection, it is expected to reduce the tumor size, lower the tumor burden, increase the surgical margin, improve the R0 resection rate, decrease the postoperative recurrence risk, and prolong the overall survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any anti-tumor treatment
the patient do not receive any anti-tumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy
Cannot have received: local or systemic treatment for recurrent HCC
Patients with recurrent HCC after surgery who have received local or systemic treatment (chemotherapy, radiotherapy, surgery, interventional therapy, ablation, alcohol injection, or molecular targeted therapy)
Lab requirements
Blood counts
HB ≥80g/L, neutrophil > 1.5×10^9/L, serum albumin > 28 g/L
Kidney function
creatinine (Cr) ≤1.5 ULN
Liver function
ALT and AST ≤5 ULN, total serum bilirubin TBIL ≤1.5 ULN, Child-Pugh grade A or B (7 points or less), ICG-R15 < 20%, sufficient future liver reserve (FLR): >40% with cirrhosis, >30% without cirrhosis
ALT and AST ≤5 ULN, total serum bilirubin TBIL ≤1.5 ULN, creatinine (Cr) ≤1.5 ULN, HB ≥80g/L, neutrophil > 1.5×10^9/L, Serum albumin > 28 g/L, Child-Pugh grade A or B (7 points or less); ICG-R15 < 20%; Sufficient future liver reserve (FLR): For patients with liver cirrhosis, FLR should be greater than 40% of the standard liver volume; for patients without liver cirrhosis, FLR should be greater than 30% of the standard liver volume.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify